Symrise AG (OTCMKTS:SYIEY – Get Free Report) was the target of a large drop in short interest in November. As of November 30th, there was short interest totalling 100 shares, a drop of 50.0% from the November 15th total of 200 shares. Based on an average daily volume of 171,200 shares, the short-interest ratio is currently 0.0 days.
Symrise Price Performance
Shares of OTCMKTS SYIEY opened at $27.14 on Friday. The company has a current ratio of 2.97, a quick ratio of 1.64 and a debt-to-equity ratio of 0.61. The company has a 50-day simple moving average of $29.25 and a 200-day simple moving average of $30.68. Symrise has a 12 month low of $24.92 and a 12 month high of $34.58.
Analysts Set New Price Targets
A number of equities research analysts have commented on SYIEY shares. Barclays upgraded Symrise to a “hold” rating in a report on Monday, November 18th. Citigroup raised Symrise to a “hold” rating in a research note on Tuesday, October 15th.
About Symrise
Symrise AG supplies fragrances, flavorings, cosmetic active ingredients and raw materials, and functional ingredients in Europe, Africa, the Middle East, North America, the Asia Pacific, and Latin America. It operates through two segments, Taste, Nutrition & Health; and Scent & Care. The Taste, Nutrition & Health segment provides functional ingredients and product solutions used in the production of food and beverages; savory flavors; natural and sustainable ingredients for food and beverage manufacturers, baby food, and dietary supplements; product solutions and services for pet food manufacturers; sustainable ingredients and services for fish feed manufacturers to develop solutions for fish and shrimp farms; and probiotics for food supplements and functional foods.
See Also
- Five stocks we like better than Symrise
- How to Invest in the FAANG Stocks
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Energy and Oil Stocks Explained
- Texas Instruments: The Old-School Tech Titan Still Delivering
- ETF Screener: Uses and Step-by-Step Guide
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Symrise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Symrise and related companies with MarketBeat.com's FREE daily email newsletter.